Equity Profile

RGEN

REPLIGEN CORP

Health CareLife Sciences Tools & Services$6.9B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Repligen Corporation (RGEN) operates in the health care sector, specifically in life sciences tools and services. The company plays a crucial role in providing products and services that support the development and manufacturing of biologic drugs, which are increasingly important in modern medicine.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is essential to gauge the company's ability to expand its market share and meet demand in the life sciences sector.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RGEN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+11.14%

Avg Stock Reaction

+4.05%

Last Quarter Recap

In Q1-2026, Repligen reported an EPS of $0.48, surpassing expectations by 25%. The stock reacted positively, gaining 6.26% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, especially given the company's strong track record of beating EPS estimates.

Bull Case

If Repligen continues its trend of exceeding EPS expectations, it could see significant stock appreciation, especially if revenue growth is also strong.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price, given the current market volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and will it exceed the previous quarter's EPS of $0.48?

Given the company's strong history of beating EPS estimates, this will be a critical factor in determining market sentiment.

How is revenue growth trending compared to previous quarters?

Investors will closely watch revenue growth to assess the company's ability to capitalize on market opportunities in the life sciences sector.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Repligen's ability to maintain its earnings momentum, especially given its recent strong performance.

Supporting Evidence

The company has consistently beaten EPS estimates, with an 88% beat rate over the last eight quarters.

Options pricing suggests a lower expected move than historical averages, indicating potential upside if results exceed expectations.

Key Risk

If EPS comes in below $0.45, it could challenge the current positive sentiment surrounding the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Repligen can maintain its strong earnings trajectory amidst competitive pressures and market conditions.

Bull Confirmed If

An EPS of $0.50 or higher would confirm the bull case, indicating continued strong performance.

Bear Confirmed If

An EPS below $0.45 would confirm the bear case, suggesting potential struggles in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±4.1%

Historical Avg

±6.4%

Pricing cheap

The options market is pricing in a modest move of about 4.1% around the earnings announcement, which is lower than the historical average.

Options are pricing a 4.1% move, but the stock has averaged a 6.4% move over the last eight quarters, indicating a potentially cheap setup.

Detail

ATM IV

0.6%

30d HV

59.6%

Calls (72K)P/C Ratio: 38.48Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$536,480.00

3,832 sh

1 insider

Net

$536,480.00

Net selling

Most Active Insiders· 1 open-market trade

Chief Executive OfficerLoeillot Olivier
$536,480.00

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Repligen beats expectations, history suggests a potential stock increase of around 3.95%, confirming ongoing strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth prospects.

Miss

A miss could lead to a decline of approximately 4.72%, signaling concerns about the company's ability to sustain its performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in their life sciences tools.
2Management's outlook on market demand for biologic drugs.
3Details on cost management strategies and their impact on margins.
4Insights into competitive pressures and how the company plans to address them.
5Any commentary on potential acquisitions or partnerships that could enhance growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is essential to gauge the company's ability to expand its market share and meet demand in the life sciences sector.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RGEN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+11.14%

Avg Stock Reaction

+4.05%

Last Quarter Recap

In Q1-2026, Repligen reported an EPS of $0.48, surpassing expectations by 25%. The stock reacted positively, gaining 6.26% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, especially given the company's strong track record of beating EPS estimates.

Bull Case

If Repligen continues its trend of exceeding EPS expectations, it could see significant stock appreciation, especially if revenue growth is also strong.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price, given the current market volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and will it exceed the previous quarter's EPS of $0.48?

Given the company's strong history of beating EPS estimates, this will be a critical factor in determining market sentiment.

How is revenue growth trending compared to previous quarters?

Investors will closely watch revenue growth to assess the company's ability to capitalize on market opportunities in the life sciences sector.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Repligen's ability to maintain its earnings momentum, especially given its recent strong performance.

Supporting Evidence

The company has consistently beaten EPS estimates, with an 88% beat rate over the last eight quarters.

Options pricing suggests a lower expected move than historical averages, indicating potential upside if results exceed expectations.

Key Risk

If EPS comes in below $0.45, it could challenge the current positive sentiment surrounding the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Repligen can maintain its strong earnings trajectory amidst competitive pressures and market conditions.

Bull Confirmed If

An EPS of $0.50 or higher would confirm the bull case, indicating continued strong performance.

Bear Confirmed If

An EPS below $0.45 would confirm the bear case, suggesting potential struggles in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±4.1%

Historical Avg

±6.4%

Pricing cheap

The options market is pricing in a modest move of about 4.1% around the earnings announcement, which is lower than the historical average.

Options are pricing a 4.1% move, but the stock has averaged a 6.4% move over the last eight quarters, indicating a potentially cheap setup.

Detail

ATM IV

0.6%

30d HV

59.6%

Calls (72K)P/C Ratio: 38.48Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$536,480.00

3,832 sh

1 insider

Net

$536,480.00

Net selling

Most Active Insiders· 1 open-market trade

Chief Executive OfficerLoeillot Olivier
$536,480.00

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Repligen beats expectations, history suggests a potential stock increase of around 3.95%, confirming ongoing strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth prospects.

Miss

A miss could lead to a decline of approximately 4.72%, signaling concerns about the company's ability to sustain its performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in their life sciences tools.
2Management's outlook on market demand for biologic drugs.
3Details on cost management strategies and their impact on margins.
4Insights into competitive pressures and how the company plans to address them.
5Any commentary on potential acquisitions or partnerships that could enhance growth.